{"slug":"vk2735","seoKey":"vk2735","displayName":"VK2735","codes":["VK2735","VK-2735","VK 2735"],"synonyms":["dual GLP-1/GIP receptor agonist"],"legalClass":"investigational","identifiers":{"wikidataQid":"Q125102011"},"approvals":[{"market":"US","status":"investigational","note":"Not approved. Queries of the approval and labelling endpoints for the development code on 2026-09-26 each returned no matches, while a control substance queried in the same run returned hits in all of them. Development runs under an investigational application; the developer reports type C and end-of-phase-2 meetings with the agency for the injection and an end-of-phase-2 meeting for the tablet, which are not approvals. No accelerated-development designation is recorded. The two phase 3 trials run at sites in the United States and Puerto Rico.","source":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:VK2735"},{"market":"EU","status":"not_approved","note":"Not approved. The official dataset of European public assessment reports, retrieved on 2026-09-26, contains neither the development code nor the developer's name, while two control substances are present in the same file. No registered trial has a site in the European Union. The European clinical trials register was not queried separately.","source":"https://www.ema.europa.eu/system/files/documents/other/medicines_output_european_public_assessment_reports_en.xlsx"},{"market":"DE","status":"not_approved","note":"Not approved. For this drug class the centralised European procedure applies, and no centralised authorisation exists; no national authorisation is apparent either. The German medicines directories were not queried by machine, so the finding is derived from the verified European negative rather than from a national register. No trial sites are registered in Germany.","source":"https://www.ema.europa.eu/system/files/documents/other/medicines_output_european_public_assessment_reports_en.xlsx"},{"market":"UK","status":"not_approved","note":"Not approved. A search of the electronic medicines compendium returned no result on 2026-09-26, while a control substance in the same run returned 6 results. The regulator's own product register is a JavaScript application and was not queryable server-side. No British trial sites are registered.","source":"https://www.medicines.org.uk/emc/search?q=VK2735"},{"market":"AU","status":"not_approved","note":"Not approved and not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-26 with no match, while control substances in the same document were found. The register of therapeutic goods was not queried directly, so the negative finding for that register is not directly evidenced. The first human study (NCT05203237, completed December 2024) ran exclusively in Australia under investigational status; no Australian trial is currently registered.","source":"https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html"},{"market":"CA","status":"not_approved","note":"Not approved. The drug product database returned an empty result for the development code, with and without hyphen, on 2026-09-26, while a control substance queried through the same endpoint in the same run returned 24 entries. No Canadian trial sites are registered.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=VK2735&type=json"},{"market":"CH","status":"not_approved","note":"Not approved. The official list of authorised human medicines with active-ingredient detail, retrieved on 2026-09-26, contains neither the development code nor the developer's name, while two control substances are present in the same file.","source":"https://www.swissmedic.ch/dam/swissmedic/de/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/Erweiterte_Arzneimittelliste%20HAM.xlsx"}],"devStage":"phase3","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT07104500","name":"VANQUISH-1 (VK2735-301) — obesity or overweight without type 2 diabetes, 78 weeks plus extension","phase":"Phase 3","n":4500,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT07104383","name":"VANQUISH-2 (VK2735-302) — obesity or overweight with type 2 diabetes, 78 weeks plus extension","phase":"Phase 3","n":1100,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT06068946","name":"VENTURE (VK2735-201) — weekly injection in obesity or overweight, 13 weeks","phase":"Phase 2","n":176,"status":"COMPLETED"},{"nct":"NCT06828055","name":"VENTURE-Oral Dosing (VK2735-202) — daily tablet in obesity or overweight, 13 weeks","phase":"Phase 2","n":280,"status":"COMPLETED"},{"nct":"NCT07838740","name":"VK2735-102 — weight maintenance with less frequent dosing","phase":"Phase 1","n":270,"status":"RECRUITING"},{"nct":"NCT05203237","name":"VK2735-101 — first-in-human single and multiple ascending doses, injection and tablet","phase":"Phase 1","n":92,"status":"COMPLETED"}],"sameAs":["https://www.wikidata.org/wiki/Q125102011"],"lastVerified":"2026-09-26","version":"1.0","published":true,"locale":"en","title":"VK2735: what the trials show, status and safety","summary":"VK2735 is an experimental peptide that switches on two gut-hormone receptors at once, GLP-1 and GIP. In trials it is given as a weekly injection, and a daily tablet containing the same molecule is also being tested. In the only fully published trial, average weight fell by 9.1 to 14.7 per cent in 13 weeks, against 1.7 per cent on placebo. Nausea and vomiting were common, and the longest controlled data cover only 33 weeks. No country has approved it, and the two phase 3 trials are due to report in the second half of 2027.","updated":"2026-09-26","url":"https://mypep.app/peptides/vk2735"}